Examkin

Question

Difficulty: MediumImmunologic and Inflammatory Processes

A 24-year-old woman is brought to the emergency department by her husband due to a 12-hour history of severe, progressively worsening abdominal pain, nausea, and multiple episodes of nonbilious vomiting. She has not had any fever, diarrhea, or melena. Her medical history is significant for several episodes of sudden-onset, nonpruritic lip and facial swelling over the past five years that typically resolved spontaneously after 2 to 3 days. Her father had a history of similar recurrent episodes of facial swelling. On physical examination, her temperature is 37.1°C (98.8°F), blood pressure is 110/70 mm Hg, pulse is 105/min, and respiratory rate is 16/min. The abdomen is diffusely tender with guarding but no rebound tenderness. There is no cutaneous rash, urticaria, or wheezing. A CT scan of the abdomen with intravenous contrast demonstrates segmental small bowel wall thickening and free pelvic fluid, without evidence of bowel obstruction. Laboratory evaluation shows a normal complete blood count, a normal basic metabolic panel, and a significantly decreased serum C4 level.

Administration of an agent with which of the following mechanisms of action is most appropriate for the acute management of this patient's current symptoms?

  1. Antagonism of bradykinin B2 receptorsAnswer
  2. B
    Agonism of alpha-1, beta-1, and beta-2 adrenergic receptors
  3. C
    Inverse agonism of peripheral H1 histamine receptors
  4. D
    Inhibition of phospholipase A2 and reduction of inflammatory cytokine transcription
  5. E
    Inhibition of angiotensin-converting enzyme to reduce kinin degradation

Answer

Antagonism of bradykinin B2 receptors
The correct answer is antagonism of bradykinin B2 receptors. This patient is presenting with a gastrointestinal attack of hereditary angioedema (HAE). HAE is an autosomal dominant immunologic disorder caused by a quantitative or functional deficiency of C1 esterase inhibitor (C1-INH). C1-INH normally inhibits the classical complement pathway and the kallikrein-kinin system. Its absence leads to unchecked activation of kallikrein, resulting in excessive production of bradykinin, the primary mediator of vascular permeability in this disease. The chronically uninhibited cleavage of C4 by C1 makes a low serum C4 level a reliable diagnostic marker. Acute attacks can cause life-threatening laryngeal edema or severe abdominal pain due to bowel wall edema, mimicking a surgical abdomen. Acute management requires targeting the specific pathophysiologic pathway, utilizing agents such as a bradykinin B2 receptor antagonist (icatibant), a kallikrein inhibitor (ecallantide), or purified C1-INH concentrate.

Step-by-Step Solution

1
Analyze the clinical presentation and history.
The patient has recurrent episodes of nonpruritic swelling, severe abdominal pain (explained by bowel wall edema on CT), and a positive family history, strongly suggesting hereditary angioedema (HAE) rather than an allergic reaction.
Differentiating bradykinin-mediated angioedema (no urticaria, GI involvement) from histamine-mediated angioedema (urticaria, wheezing) is critical for acute management.
2
Evaluate the laboratory findings.
The significantly decreased serum C4 level confirms classical complement pathway consumption.
Low C4 is the primary screening test for C1 esterase inhibitor (C1-INH) deficiency, the underlying cause of HAE.
3
Identify the underlying immunopathologic mechanism.
C1-INH deficiency leads to uninhibited activation of the kallikrein-kinin system, resulting in massive overproduction of bradykinin, which causes profound vasodilation and increased vascular permeability.
Understanding the precise inflammatory mediator dictates the choice of pharmacotherapy.
4
Select the appropriate pharmacologic intervention.
Acute management of HAE requires blocking the effects of bradykinin (e.g., icatibant, a bradykinin B2 receptor antagonist), inhibiting kallikrein (ecallantide), or replacing C1-INH.
Standard allergic treatments (epinephrine, antihistamines, corticosteroids) are ineffective for bradykinin-mediated edema.

Key Concept

Pathophysiology and targeted pharmacotherapy of Hereditary Angioedema (HAE).
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic